Cargando…

The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study

INTRODUCTION: Immunosuppressive agents (ISA) have been used in multiple sclerosis (MS) for decades, frequently as off label licensed therapies. Given the new MS treatment landscape, what place do ISA have in combating MS? METHODS: We conducted a retrospective multicentre study to investigate the fre...

Descripción completa

Detalles Bibliográficos
Autores principales:	D’Amico, Emanuele, Leone, Carmela, Graziano, Giusi, Amato, Maria Pia, Bergamaschi, Roberto, Cavalla, Paola, Coniglio, Gabriella, Di Battista, Giancarlo, Ferrò, Maria Teresa, Granella, Franco, Granieri, Enrico, Lugaresi, Alessandra, Lus, Giacomo, Millefiorini, Enrico, Pozzilli, Carlo, Tedeschi, Gioacchino, Zappia, Mario, Comi, Giancarlo, Trojano, Maria, Lepore, Vito, Patti, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922668/ https://www.ncbi.nlm.nih.gov/pubmed/27348606 http://dx.doi.org/10.1371/journal.pone.0157721

Ejemplares similares

Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study
por: Iaffaldano, Pietro, et al.
Publicado: (2022)

The Italian multiple sclerosis register
por: Trojano, Maria, et al.
Publicado: (2018)

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience
por: D’Amico, Emanuele, et al.
Publicado: (2018)

Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register
por: Mosconi, Paola, et al.
Publicado: (2023)

Evaluation of Drug Utilization Patterns during Initial Treatment in the Emergency Room: A Retroprospective Pharmacoepidemiological Study
por: Cheekavolu, Chakrapani, et al.
Publicado: (2011)

Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies
por: Iaffaldano, Pietro, et al.
Publicado: (2021)

Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis
por: Sormani, Maria P., et al.
Publicado: (2021)

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
por: Patti, F, et al.
Publicado: (2016)

A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives
por: D’Amico, Emanuele, et al.
Publicado: (2016)

COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context
por: Sormani, Maria Pia, et al.
Publicado: (2021)

First‐line therapies in late‐onset multiple sclerosis: An Italian registry study
por: Zanghì, Aurora, et al.
Publicado: (2021)

Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study
por: Pastò, Luisa, et al.
Publicado: (2012)

Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study
por: Pecori, Chiara, et al.
Publicado: (2014)

Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study
por: Giannini, Marta, et al.
Publicado: (2012)

Negative prognostic impact of MRI spinal lesions in the early stages of relapsing–remitting multiple sclerosis
por: D’Amico, E, et al.
Publicado: (2016)

A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis
por: Ponzano, Marta, et al.
Publicado: (2022)

Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study
por: Comi, Giancarlo, et al.
Publicado: (2020)

Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)
por: Chisari, Clara G., et al.
Publicado: (2023)

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS
por: Ghezzi, Angelo, et al.
Publicado: (2019)

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial
por: Laroni, Alice, et al.
Publicado: (2014)

Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic
por: Zanghì, Aurora, et al.
Publicado: (2022)

Histopathological correlation of adenomyosis and leiomyoma in hysterectomy specimens as the cause of abnormal uterine bleeding in women in different age groups in the Kumaon region: A retroprospective study
por: Rizvi, Ghazala, et al.
Publicado: (2013)

Changes in John Cunningham Virus Index in Multiple Sclerosis Patients Treated with Different Disease-Modifying Therapies
por: Sgarlata, Eleonora, et al.
Publicado: (2022)

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)
por: Comi, Giancarlo, et al.
Publicado: (2017)

Machine learning for prediction of sudden cardiac death in heart failure patients with low left ventricular ejection fraction: study protocol for a retroprospective multicentre registry in China
por: Meng, Fanqi, et al.
Publicado: (2019)

Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus
por: Filippi, Massimo, et al.
Publicado: (2021)

Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
por: Filippi, Massimo, et al.
Publicado: (2022)

Correction to: Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
por: Filippi, Massimo, et al.
Publicado: (2022)

1,25(OH)(2)D3 Differently Modulates the Secretory Activity of IFN-DC and IL4-DC: A Study in Cells from Healthy Donors and MS Patients
por: Sanseverino, Isabella, et al.
Publicado: (2023)

Natalizumab in the pediatric MS population: results of the Italian registry
por: Ghezzi, Angelo, et al.
Publicado: (2015)

Intracranial extension of orbital inflammatory pseudotumor: a case report and literature review
por: Tedeschi, Enrico, et al.
Publicado: (2016)

Magnetic Resonance Imaging correlates of benign and malignant alterations of the spinal bone marrow
por: Caranci, Ferdinando, et al.
Publicado: (2018)

Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study
por: Zanghì, Aurora, et al.
Publicado: (2021)

Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy
por: Castellazzi, Massimiliano, et al.
Publicado: (2016)

The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis
por: Rocca, Maria A., et al.
Publicado: (2017)

Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment
por: Castellazzi, Massimiliano, et al.
Publicado: (2015)

Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register
por: D’Amico, Emanuele, et al.
Publicado: (2021)

Textbook Outcome of Laparoscopic Microwave Ablation for Hepatocellular Carcinoma
por: Lanari, Jacopo, et al.
Publicado: (2023)

Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study
por: Amato, Maria Pia, et al.
Publicado: (2023)

Relation of sensorimotor and cognitive cerebellum functional connectivity with brain structural damage in patients with multiple sclerosis and no disability
por: Tommasin, Silvia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_58t1esb8kucfslnf44knu72dvm